{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:54:15Z","timestamp":1793717655309,"version":"4.6.1"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BG2024007"],"award-info":[{"award-number":["BG2024007"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20241311"],"award-info":[{"award-number":["BK20241311"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20243047"],"award-info":[{"award-number":["BK20243047"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2242024K40041"],"award-info":[{"award-number":["2242024K40041"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008081","name":"Southeast University","doi-asserted-by":"publisher","award":["RF1028623361"],"award-info":[{"award-number":["RF1028623361"]}],"id":[{"id":"10.13039\/501100008081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404603"],"award-info":[{"award-number":["82404603"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32402218"],"award-info":[{"award-number":["32402218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jconrel.2025.114048","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T15:02:40Z","timestamp":1752937360000},"page":"114048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Advances in RNA therapeutics and its delivery strategies against Multiple Myeloma"],"prefix":"10.1016","volume":"385","author":[{"given":"Kaiwen","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongkun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Amiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jconrel.2025.114048_bb0005","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"27\u201328","key":"10.1016\/j.jconrel.2025.114048_bb0010","first-page":"470","article-title":"The diagnosis and treatment of multiple Myeloma","volume":"113","author":"Gerecke","year":"2016","journal-title":"Dtsch \u00c4rztebl Int."},{"key":"10.1016\/j.jconrel.2025.114048_bb0015","author":"Cancer Today"},{"issue":"9","key":"10.1016\/j.jconrel.2025.114048_bb0020","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2025.114048_bb0035","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.jconrel.2025.114048_bb0040","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple Myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol. Biomed."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1517\/14728222.2015.1071355","article-title":"RNA interference for multiple myeloma therapy: targeting signal transduction pathways","volume":"20","author":"Guo","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jconrel.2025.114048_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154704","article-title":"miRNAs driving diagnosis, progression, and drug resistance in multiple myeloma","volume":"248","author":"Elkady","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114048_bb0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNA target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2025.114048_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155401","article-title":"A comprehensive review of the PTEN\/PI3K\/Akt axis in multiple myeloma: from molecular interactions to potential therapeutic targets","volume":"260","author":"Alimohammadi","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114048_bb0070","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3892\/mmr.2021.12288","article-title":"Long non-coding RNA DANCR represses the viability, migration and invasion of multiple myeloma cells by sponging miR-135b-5p to target KLF9","volume":"24","author":"Wu","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0075","article-title":"LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt\/\u03b2-catenin\/cyclin D1 signaling via PLAGL2","volume":"38","author":"Q L","year":"2022","journal-title":"Cell Biol. Toxicol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22008","article-title":"LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a\/MCL1 pathway","volume":"32","author":"Wu","year":"2018","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0085","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Sign. Transduct. Target Ther."},{"key":"10.1016\/j.jconrel.2025.114048_bb0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/ITT.S306103","article-title":"Immunotherapy of multiple Myeloma: promise and challenges","volume":"10","author":"Abramson","year":"2021","journal-title":"Immuno. Targets Ther."},{"issue":"23","key":"10.1016\/j.jconrel.2025.114048_bb0095","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class\u2013exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2024","key":"10.1016\/j.jconrel.2025.114048_bb0105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-cancerbio-061421-014236","article-title":"Next-generation therapies for multiple Myeloma","volume":"8","author":"Meermeier","year":"2024","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.jconrel.2025.114048_bb0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.12703\/r\/11-28","article-title":"Recent advances in the treatment of multiple myeloma: a brief review","volume":"11","author":"Bobin","year":"2022","journal-title":"Fac. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114048_bb0115","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114048_bb0120","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","article-title":"Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma","volume":"35","author":"Lin","year":"2021","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.jconrel.2025.114048_bb0125","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood-2024-208664","article-title":"Preclinical proof-of-concept of a novel mRNA-based therapeutic combination of an FcRH5 targeted NK cell engager and an IL-15 superagonist for the treatment of multiple Myeloma","volume":"144","author":"Bai","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.114048_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.139186","article-title":"Antisense oligonucleotides-based approaches for the treatment of multiple myeloma","volume":"291","author":"Oprea","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2025.114048_bb0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jconrel.2024.10.003","article-title":"Recent advances in targeted drug delivery systems for multiple myeloma","volume":"376","author":"Pant","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114048_bb0140","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2024-209444","article-title":"Lipid nanoparticle-mediated combinational mRNA vaccine for multiple Myeloma: the next stage of cancer immunotherapy","volume":"144","author":"Dutta","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.114048_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216081","article-title":"Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment","volume":"556","author":"Tang","year":"2023","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/ncrna9060068","article-title":"Dysregulation of non-coding RNAs: roles of miRNAs and lncRNAs in the pathogenesis of multiple Myeloma","volume":"9","author":"Ismail","year":"2023","journal-title":"Non-Cod. RNA"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.arcmed.2023.05.002","article-title":"Hsa_circ_0111738 inhibits tumor progression and angiogenesis in multiple Myeloma by sponging miR-1233-3p to regulate HIF-1 signaling pathway","volume":"54","author":"Wang","year":"2023","journal-title":"Arch. Med. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0160","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20182502","article-title":"Increased expression of miR-27 predicts poor prognosis and promotes tumorigenesis in human multiple myeloma","volume":"39","author":"Che","year":"2019","journal-title":"Biosci. Rep."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0165","first-page":"10001","article-title":"Effects of microRNA-20a on the proliferation, migration and apoptosis of multiple myeloma via the PTEN\/PI3K\/AKT signaling pathway","volume":"15","author":"Jiang","year":"2018","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2017.99","article-title":"Non-coding RNA networks in cancer","volume":"18","author":"Anastasiadou","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.114048_bb0175","first-page":"98","article-title":"Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response","volume":"10","author":"Hashemi","year":"2025","journal-title":"Non-Cod. RNA Res."},{"issue":"9","key":"10.1016\/j.jconrel.2025.114048_bb0180","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.3390\/ijms21093387","article-title":"The interplay between MicroRNAs and the components of the tumor microenvironment in B-Cell Malignancies","volume":"21","author":"El-Daly","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2025.114048_bb0185","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1016\/j.clml.2020.05.026","article-title":"Role of the bone marrow Milieu in multiple Myeloma progression and therapeutic resistance","volume":"20","author":"Ho","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114048_bb0190","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/s41375-021-01147-y","article-title":"Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma","volume":"35","author":"Carrasco-Leon","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0195","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12935-023-03028-z","article-title":"CircRNAs in diagnosis, prognosis, and clinicopathological features of multiple myeloma; a systematic review and meta-analysis","volume":"23","author":"Mirazimi","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"60","key":"10.1016\/j.jconrel.2025.114048_bb0200","doi-asserted-by":"crossref","first-page":"101984","DOI":"10.18632\/oncotarget.21957","article-title":"LncRNA MALAT1 acts as an oncogene in multiple myeloma through sponging miR-509-5p to modulate FOXP1 expression","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2025.114048_bb0205","article-title":"MicroRNA-138 promotes the progression of multiple myeloma through targeting paired PAX5","volume":"829","author":"Yan","year":"2024","journal-title":"Mutat. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0210","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s13018-023-03832-3","article-title":"Circ_0005615 restrains the progression of multiple myeloma through modulating miR-331-3p and IGF1R regulatory cascade","volume":"18","author":"Zhang","year":"2023","journal-title":"J. Orthop. Surg."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0215","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2422154","article-title":"LncRNA MALAT1 silencing represses CXCL12-induced proliferation, invasion, and homing behavior in multiple myeloma by inhibiting CXCR4","volume":"29","author":"Ning","year":"2024","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0220","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jphs.2022.01.013","article-title":"Circular RNA circPSAP functions as an efficient miR-331-3p sponge to regulate proliferation, apoptosis and bortezomib sensitivity of human multiple myeloma cells by upregulating HDAC4","volume":"149","author":"Ma","year":"2022","journal-title":"J. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0225","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/15548627.2019.1635380","article-title":"MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4","volume":"16","author":"Wu","year":"2019","journal-title":"Autophagy"},{"key":"10.1016\/j.jconrel.2025.114048_bb0230","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1182\/blood-2023-177912","article-title":"Targeting IGF1R\/Insr pathway with approved ALK-inhibitors overcomes proteasome inhibitor resistance in multiple Myeloma","volume":"142","author":"Mendez-Lopez","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114048_bb0235","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1038\/leu.2015.124","article-title":"Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo","volume":"29","author":"Morelli","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114048_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.175","article-title":"miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1","volume":"3","author":"Amodio","year":"2012","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114048_bb0245","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41375-020-0947-1","article-title":"miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma","volume":"35","author":"Rossi","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jconrel.2025.114048_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114647","article-title":"IL-17\/miR-192\/IL-17Rs regulatory feedback loop facilitates multiple Myeloma progression","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0255","first-page":"160","article-title":"Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma","volume":"26","author":"Yin","year":"2021","journal-title":"Hematol. Amst. Neth."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0260","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41416-021-01602-8","article-title":"miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome","volume":"126","author":"Papadimitriou","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0265","first-page":"291","article-title":"Effects of miR-181a on the biological function of multiple myeloma","volume":"42","author":"Liu","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2025.114048_bb0270","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12935-020-1118-1","article-title":"Knockdown of lncRNA SNHG16 suppresses multiple myeloma cell proliferation by sponging miR-342-3p","volume":"20","author":"Yang","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"3\u20134","key":"10.1016\/j.jconrel.2025.114048_bb0275","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41417-021-00309-5","article-title":"The LncRNA RP11-301G19.1\/miR-582-5p\/HMGB2 axis modulates the proliferation and apoptosis of multiple myeloma cancer cells via the PI3K\/AKT signalling pathway","volume":"29","author":"Wang","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0280","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1080\/21655979.2021.1920325","article-title":"MicroRNA miR-188-5p as a mediator of long non-coding RNA MALAT1 regulates cell proliferation and apoptosis in multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Bioengineered"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114048_bb0285","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00432-020-03127-8","article-title":"Long non-coding RNA MALAT1 facilitates the tumorigenesis, invasion and glycolysis of multiple myeloma via miR-1271-5p\/SOX13 axis","volume":"146","author":"Liu","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0290","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/dna.2023.0288","article-title":"Circular RNA circXPO1 promotes multiple myeloma progression by regulating miR-495-3p\/DNA damage-induced transcription 4 Axis","volume":"43","author":"Li","year":"2024","journal-title":"DNA Cell Biol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114048_bb0295","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00382-19","article-title":"Long noncoding RNA H19 promotes tumorigenesis of multiple Myeloma by activating BRD4 signaling by targeting MicroRNA 152-3p","volume":"40","author":"Zheng","year":"2020","journal-title":"Mol. Cell. Biol."},{"issue":"Supplement 1","key":"10.1016\/j.jconrel.2025.114048_bb0300","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood-2023-187762","article-title":"The Spop\/BRD4\/c-Myc axis modulates IMiDs sensitivity in multiple Myeloma","volume":"142","author":"Xing","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0305","first-page":"596","article-title":"Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients","volume":"27","author":"Zhou","year":"2022","journal-title":"Hematol. Amst. Neth."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0310","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/0008-5472.CAN-13-3311-T","article-title":"miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt\/\u03b2-catenin\/BCL9 pathway","volume":"74","author":"Zhao","year":"2014","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0315","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4149\/neo_2021_210205N184","article-title":"LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN","volume":"68","author":"Yang","year":"2021","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112280","article-title":"Dysregulation of LncRNA ANRIL mediated by miR-411-3p inhibits the malignant proliferation and tumor stem cell like property of multiple myeloma via hypoxia-inducible factor 1\u03b1","volume":"396","author":"Wang","year":"2020","journal-title":"Exp. Cell Res."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0325","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cmet.2020.08.002","article-title":"The role of HIF in immunity and inflammation","volume":"32","author":"McGettrick","year":"2020","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0330","article-title":"Long non-coding RNA NEAT1 promotes multiple myeloma malignant transformation via targeting miR-485-5p\/ABCB8","volume":"29","author":"Xu","year":"2024","journal-title":"Hematol. Amst. Neth."},{"key":"10.1016\/j.jconrel.2025.114048_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173752","article-title":"Lnc NEAT1\/miR-29b-3p\/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells","volume":"891","author":"Che","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.jconrel.2025.114048_bb0340","doi-asserted-by":"crossref","first-page":"10532","DOI":"10.18632\/oncotarget.3300","article-title":"Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells","volume":"6","author":"De Veirman","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2025.114048_bb0345","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.molimm.2019.10.026","article-title":"LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7-H3 in multiple myeloma","volume":"117","author":"Gao","year":"2020","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0350","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12979-021-00258-5","article-title":"Knockdown of lncRNA BDNF-AS inhibited the progression of multiple myeloma by targeting the miR-125a\/b-5p-BCL2 axis","volume":"19","author":"Chu","year":"2022","journal-title":"Immun. Age A."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114048_bb0355","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3892\/ijmm.2020.4670","article-title":"miR-144-3p inhibits the proliferation, migration and angiogenesis of multiple myeloma cells by targeting myocyte enhancer factor 2A","volume":"46","author":"Tian","year":"2020","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.jconrel.2025.114048_bb0360","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12935-020-01234-7","article-title":"Long non-coding RNA OIP5-AS1 suppresses multiple myeloma progression by sponging miR-27a-3p to activate TSC1 expression","volume":"20","author":"Wang","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.jconrel.2025.114048_bb0365","article-title":"A review on the role of oncogenic lncRNA OIP5-AS1 in human malignancies","volume":"137","author":"Ghafouri-Fard","year":"2021","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114048_bb0370","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.bbrc.2015.11.136","article-title":"miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1","volume":"469","author":"Liu","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.jconrel.2025.114048_bb0375","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/s41375-018-0161-6","article-title":"Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche","volume":"32","author":"Tsukamoto","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114048_bb0380","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1038\/s41375-018-0140-y","article-title":"Dysregulation of EZH2\/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS","volume":"32","author":"Rastgoo","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0385","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3390\/cancers11040475","article-title":"HDAC inhibitors exert Anti-Myeloma effects through multiple modes of action","volume":"11","author":"Imai","year":"2019","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.jconrel.2025.114048_bb0390","first-page":"9238","article-title":"Long noncoding RNA UCA1 regulates proliferation and apoptosis in multiple myeloma by targeting miR-331-3p\/IL6R axis for the activation of JAK2\/STAT3 pathway","volume":"23","author":"Li","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2025.114048_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106785","article-title":"MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner","volume":"114","author":"Liu","year":"2022","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114048_bb0400","first-page":"389","article-title":"MicroRNA-1179 targets Epiregulin (EREG) regulates the proliferation and metastasis of human multiple myeloma cells","volume":"70","author":"Liu","year":"2023","journal-title":"Acta Biochim. Pol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114048_bb0405","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ymthe.2019.01.012","article-title":"miR-221\/222-mediated inhibition of autophagy promotes dexamethasone resistance in multiple Myeloma","volume":"27","author":"Xu","year":"2019","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114048_bb0410","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23168","article-title":"MicroRNA-146b overexpression associates with deteriorated clinical characteristics, increased International Staging System stage, cacoethic chromosome abnormality, and unfavorable prognosis in multiple myeloma patients","volume":"34","author":"Bao","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114048_bb0415","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.3324\/haematol.2017.168070","article-title":"Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory\/relapsed multiple myeloma","volume":"102","author":"Jung","year":"2017","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.jconrel.2025.114048_bb0420","doi-asserted-by":"crossref","first-page":"19589","DOI":"10.18632\/oncotarget.7319","article-title":"Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis","volume":"7","author":"Hao","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114048_bb0425","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.3390\/ijms25116065","article-title":"Circulating miR-16 and miR-21 Levels in Multiple Myeloma: Prognostic Significance of Survival and Response to Lenalidomide Treatment","volume":"25","author":"Gkioka","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.jconrel.2025.114048_bb0430","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/15384101.2019.1632138","article-title":"miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1","volume":"18","author":"Yuan","year":"2019","journal-title":"Cell Cycle Georget. Tex."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114048_bb0435","first-page":"754","article-title":"Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias","volume":"4","author":"De Matos","year":"2023","journal-title":"Nat. Can."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0440","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0445","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nrc1631","article-title":"Antisense therapy for cancer","volume":"5","author":"Gleave","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.114048_bb0450","series-title":"The Molecular Basis of Cancer","first-page":"19","article-title":"2 - Oncogenes and Signal Transduction","author":"Grumolato","year":"2015"},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0455","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/sj.leu.2403363","article-title":"G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma","volume":"18","author":"van de Donk","year":"2004","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114048_bb0460","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1182\/blood.V104.11.2400.2400","article-title":"Phase II trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in relapsed multiple Myeloma patients (Pts)","volume":"104","author":"Badros","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0465","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/cdd.2008.37","article-title":"Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?","volume":"15","author":"Labi","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2025.114048_bb0470","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/asheducation-2003.1.248","article-title":"Advances in biology and therapy of multiple myeloma","author":"Barill\u00e9-Nion","year":"2003","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.jconrel.2025.114048_bb0475","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biomaterials.2018.12.033","article-title":"Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo","volume":"197","author":"Ma","year":"2019","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0480","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V100.1.194","article-title":"Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells","volume":"100","author":"Derenne","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jconrel.2025.114048_bb0485","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/0008-5472.CAN-18-2799","article-title":"An HK2 antisense oligonucleotide induces synthetic lethality in HK1-HK2+ multiple Myeloma","volume":"79","author":"Xu","year":"2019","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.jconrel.2025.114048_bb0490","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2018-03-836601","article-title":"Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92","volume":"132","author":"Morelli","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jconrel.2025.114048_bb0495","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/s41375-018-0067-3","article-title":"Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity","volume":"32","author":"Amodio","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2025.114048_bb0500","article-title":"LINC01432 binds to CELF2 in newly diagnosed multiple myeloma promoting short progression-free survival to standard therapy","author":"Mishra","year":"2025","journal-title":"Res. Sq."},{"issue":"16","key":"10.1016\/j.jconrel.2025.114048_bb0505","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/blood.2023021991","article-title":"An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma","volume":"144","author":"Grillone","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0510","first-page":"427","article-title":"Antisense therapy in malignant diseases: status quo and quo vadis?","volume":"110","author":"Tamm","year":"2006","journal-title":"Clin. Sci. Lond Engl. 1979"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114048_bb0515","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1172\/JCI115355","article-title":"Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines","volume":"88","author":"Levy","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2025.114048_bb0520","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood-2019-129286","article-title":"ILF2 antisense oligonucleotide therapy and a CRISPR\/Cas9-based screening for DNA repair effectors identify synthetic lethal approaches enhancing myeloma cells sensitivity to DNA damage","volume":"134","author":"Thongon","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.114048_bb0525","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/s41467-024-45350-8","article-title":"Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma","volume":"15","author":"Thongon","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0530","first-page":"1","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Sign. Transduct. Target Ther."},{"issue":"21","key":"10.1016\/j.jconrel.2025.114048_bb0535","article-title":"Delivery of therapeutic RNA to the bone marrow in multiple Myeloma using CD38-targeted lipid nanoparticles","volume":"10","author":"Tarab-Ravski","year":"2023","journal-title":"Adv. Sci."},{"issue":"25","key":"10.1016\/j.jconrel.2025.114048_bb0540","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215711120","article-title":"In vivo bone marrow microenvironment siRNA delivery using lipid-polymer nanoparticles for multiple myeloma therapy","volume":"120","author":"Guimar\u00e3es","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0545","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12195-023-00774-y","article-title":"siRNA lipid\u2013polymer nanoparticles targeting E-selectin and Cyclophilin A in bone marrow for combination multiple myeloma therapy","volume":"16","author":"Figueroa-Espada","year":"2023","journal-title":"Cell. Mol. Bioeng."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0550","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/biomedicines9040433","article-title":"The challenges and strategies of antisense oligonucleotide drug delivery","volume":"9","author":"Gagliardi","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102437","article-title":"Development, opportunities, and challenges of siRNA nucleic acid drugs","volume":"36","author":"Xiao","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.114048_bb0560","doi-asserted-by":"crossref","first-page":"17579","DOI":"10.1038\/srep17579","article-title":"Delivery of miR-34a by chitosan\/PLGA nanoplexes for the anticancer treatment of multiple myeloma","volume":"5","author":"Cosco","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.114048_bb0565","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-1-4939-3999-2_12","article-title":"Subcutaneous murine xenograft models: a critical tool for studying human tumor growth and angiogenesis in vivo","volume":"1464","author":"Schmidt","year":"2016","journal-title":"Methods Mol. Biol. Clifton NJ"},{"issue":"9","key":"10.1016\/j.jconrel.2025.114048_bb0570","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/jpm12091428","article-title":"MiRNA as a potential target for multiple Myeloma therapy\u2013current knowledge and perspectives","volume":"12","author":"Szudy-Szczyrek","year":"2022","journal-title":"J. Pers. Med."},{"issue":"12","key":"10.1016\/j.jconrel.2025.114048_bb0575","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41417-020-00291-4","article-title":"Roles of miRNA dysregulation in the pathogenesis of multiple myeloma","volume":"28","author":"Chen","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2025.114048_bb0580","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.leukres.2015.10.004","article-title":"Small interfering RNA silencing of interleukin-6 in mesenchymal stromal cells inhibits multiple myeloma cell growth","volume":"40","author":"Teoh","year":"2016","journal-title":"Leuk. Res."},{"issue":"10","key":"10.1016\/j.jconrel.2025.114048_bb0585","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/0008-5472.CAN-19-1077","article-title":"Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple Myeloma","volume":"80","author":"Hu","year":"2020","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114048_bb0590","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/hum.2018.145","article-title":"Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T-cell response","volume":"30","author":"Foster","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0595","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ymthe.2019.01.018","article-title":"The emerging role of in vitro-transcribed mRNA in adoptive T cell immunotherapy","volume":"27","author":"Foster","year":"2019","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0600","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41417-023-00587-1","article-title":"Clinical trials of self-replicating RNA-based cancer vaccines","volume":"30","author":"Morse","year":"2023","journal-title":"Cancer Gene Ther."},{"issue":"12","key":"10.1016\/j.jconrel.2025.114048_bb0605","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1038\/s41375-020-0828-7","article-title":"Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma","volume":"34","author":"Packiriswamy","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jconrel.2025.114048_bb0610","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of edmonston strain of measles virus, genetically engineered to express the Sodium Iodide Symporter in patients with recurrent or refractory multiple Myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2025.114048_bb0615","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","article-title":"Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines","volume":"348","author":"Liu","year":"2022","journal-title":"J. Control Release Off. J. Control Release Soc."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0620","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-018-0569-5","article-title":"Circular RNAs: a new frontier for cancer diagnosis and therapy","volume":"11","author":"Zhang","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0625","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41576-024-00806-x","article-title":"The therapeutic potential of circular RNAs","volume":"26","author":"O\u2019Leary","year":"2025","journal-title":"Nat. Rev. Genet."},{"issue":"14","key":"10.1016\/j.jconrel.2025.114048_bb0630","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.7150\/thno.77350","article-title":"Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114048_bb0635","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticlesfrom Liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0640","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0169-409X(02)00021-2","article-title":"The origin of pegnology","volume":"54","author":"Davis","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0645","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41565-024-01847-3","article-title":"Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors","volume":"20","author":"Hofstraat","year":"2025","journal-title":"Nat. Nanotechnol."},{"issue":"9","key":"10.1016\/j.jconrel.2025.114048_bb0650","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Ma","year":"2024","journal-title":"Chem. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114048_bb0655","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1021\/acs.biomac.8b01553","article-title":"Nanogels enable efficient miRNA delivery and target gene downregulation in transfection-resistant multiple Myeloma cells","volume":"20","author":"Zilkowski","year":"2019","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2025.114048_bb0660","series-title":"Progress in Molecular Biology and Translational Science","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/bs.pmbts.2024.01.001","article-title":"Chapter Nine - Advances in the polymeric nanoparticulate delivery systems for RNA therapeutics","volume":"204","author":"Sristi","year":"2024"},{"issue":"8","key":"10.1016\/j.jconrel.2025.114048_bb0665","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1021\/acs.bioconjchem.1c00211","article-title":"Gold nanoparticles as carriers for functional RNA nanostructures","volume":"32","author":"Graczyk","year":"2021","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0670","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004381","article-title":"Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis","volume":"10","author":"Guo","year":"2022","journal-title":"J. Immunother. Cancer."},{"issue":"22","key":"10.1016\/j.jconrel.2025.114048_bb0675","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1021\/acs.nanolett.4c01511","article-title":"Black phosphorus quantum dot loaded bioinspired nanoplatform synergized with aPD-L1 for multimode cancer immunotherapy","volume":"24","author":"Cao","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2025.114048_bb0680","first-page":"360","article-title":"The exploration of quantum dot-molecular beacon based MoS2 fluorescence probing for myeloma-related Mirnas detection","volume":"17","author":"Wang","year":"2022","journal-title":"Bioact. Mater."},{"issue":"4_suppl","key":"10.1016\/j.jconrel.2025.114048_bb0685","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/jco.2016.34.4_suppl.385","article-title":"A phase Ib\/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma","volume":"34","author":"Schultheis","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0690","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1634\/theoncologist.2018-0838","article-title":"An open-label, multicenter, Phase I, dose escalation study with Phase II Expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of intravenous TKM-080301 in subjects with advanced Hepatocellular Carcinoma","volume":"24","author":"El Dika","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0695","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s44178-023-00042-z","article-title":"A personalized mRNA vaccine has exhibited potential in the treatment of pancreatic cancer","volume":"2","author":"Kang","year":"2023","journal-title":"Holist. Integr. Oncol."},{"key":"10.1016\/j.jconrel.2025.114048_bb0700","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","article-title":"Lipid nanoparticles for siRNA delivery in cancer treatment","volume":"361","author":"El Moukhtari","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114048_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114614","article-title":"The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0710","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0715","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/pharmaceutics10040205","article-title":"Targeted nanomedicine to treat bone metastasis","volume":"10","author":"Adjei","year":"2018","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0720","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ymthe.2025.02.047","article-title":"Using aptamers for targeted delivery of RNA therapies","volume":"33","author":"Driscoll","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.114048_bb0725","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.omtn.2019.10.021","article-title":"An anti-BCMA RNA aptamer for miRNA intracellular delivery","volume":"18","author":"Catuogno","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"49","key":"10.1016\/j.jconrel.2025.114048_bb0730","doi-asserted-by":"crossref","first-page":"45455","DOI":"10.1021\/acsami.9b16637","article-title":"Aptamer-based erythrocyte-derived mimic vesicles loaded with siRNA and doxorubicin for the targeted treatment of multidrug-resistant tumors","volume":"11","author":"Wang","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"8","key":"10.1016\/j.jconrel.2025.114048_bb0735","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1073\/pnas.1620874114","article-title":"Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics","volume":"114","author":"Dahlman","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"49","key":"10.1016\/j.jconrel.2025.114048_bb0740","doi-asserted-by":"crossref","first-page":"17095","DOI":"10.1021\/jacs.8b08976","article-title":"Nanoparticles that deliver RNA to bone marrow identified by in vivo directed evolution","volume":"140","author":"Sago","year":"2018","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114048_bb0745","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41551-020-00623-7","article-title":"Nanoparticle-encapsulated siRNAs for gene silencing in the haematopoietic stem-cell niche","volume":"4","author":"Krohn-Grimberghe","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114048_bb0750","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1385\/MO:19:2:87","article-title":"Expression of MDR1\/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma","volume":"19","author":"Schwarzenbach","year":"2002","journal-title":"Med. Oncol."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114048_bb0755","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00277-010-0992-3","article-title":"Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin","volume":"89","author":"Buda","year":"2010","journal-title":"Ann. Hematol."},{"issue":"44","key":"10.1016\/j.jconrel.2025.114048_bb0760","doi-asserted-by":"crossref","first-page":"75924","DOI":"10.18632\/oncotarget.18237","article-title":"RECQ1 expression is upregulated in response to DNA damage and in a p53-dependent manner","volume":"8","author":"Parvathaneni","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.jconrel.2025.114048_bb0765","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1182\/blood-2005-10-009084","article-title":"ABCG2 expression, function, and promoter methylation in human multiple myeloma","volume":"108","author":"Turner","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114048_bb0770","first-page":"256","article-title":"BCL-X expression in multiple myeloma: possible indicator of Chemoresistance1","volume":"58","author":"Tu","year":"1998","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.jconrel.2025.114048_bb0775","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1182\/blood.V128.22.3277.3277","article-title":"MAGE-a mediate resistance to chemotherapy in multiple Myeloma through regulation of Bcl-2 proteins","volume":"128","author":"Cho","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jconrel.2025.114048_bb0780","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/jnci\/85.8.632","article-title":"Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs","volume":"85","author":"Chaudhary","year":"1993","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"18","key":"10.1016\/j.jconrel.2025.114048_bb0785","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jconrel.2025.114048_bb0790","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon\u2013DDB1\u2013lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6168","key":"10.1016\/j.jconrel.2025.114048_bb0795","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple Myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"issue":"7201","key":"10.1016\/j.jconrel.2025.114048_bb0800","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.114048_bb0805","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2019-125818","article-title":"The impact and modulation of microenvironment-induced immune resistance against CAR T Cell and antibody treatments in multiple Myeloma","volume":"134","author":"Holthof","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0810","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0815","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0820","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0825","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: How cancer cells resist CAR T cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"19","key":"10.1016\/j.jconrel.2025.114048_bb0830","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.114048_bb0835","first-page":"13","article-title":"Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation","author":"Khan","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114048_bb0840","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114048_bb0845","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.jconrel.2025.114048_bb0850","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics \u2014 challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0855","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2022.0061","article-title":"Considerations in the preclinical assessment of the safety of antisense oligonucleotides","volume":"33","author":"Goyenvalle","year":"2023","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.jconrel.2025.114048_bb0860","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9954443","article-title":"Toxicity of nanoparticles in biomedical application: nanotoxicology","volume":"2021","author":"Egbuna","year":"2021","journal-title":"J. Toxicol."},{"key":"10.1016\/j.jconrel.2025.114048_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124799","article-title":"Effects of nanoparticle size, shape, and zeta potential on drug delivery","volume":"666","author":"\u00d6zt\u00fcrk","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.114048_bb0870","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s11671-018-2457-x","article-title":"Dependence of nanoparticle toxicity on their physical and chemical properties","volume":"13","author":"Sukhanova","year":"2018","journal-title":"Nanoscale Res. Lett."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114048_bb0875","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","article-title":"Strategies to reduce the risks of mRNA drug and vaccine toxicity","volume":"23","author":"Bitounis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0880","doi-asserted-by":"crossref","first-page":"18071","DOI":"10.1038\/s41598-022-23013-2","article-title":"Development of lipid nanoparticles and liposomes reference materials (II): cytotoxic profiles","volume":"12","author":"Syama","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.114048_bb0885","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.567365","article-title":"Opsonins and dysopsonins of nanoparticles: facts, concepts, and methodological guidelines","volume":"11","author":"Papini","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0890","doi-asserted-by":"crossref","first-page":"28805","DOI":"10.1038\/s41598-024-80263-y","article-title":"Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy","volume":"14","author":"Behsen","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114048_bb0895","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114048_bb0900","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bone.2015.04.004","article-title":"A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease","volume":"77","author":"Paton-Hough","year":"2015","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114048_bb0905","first-page":"609","article-title":"Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL\/KaLwRij mice","volume":"122","author":"Radl","year":"1979","journal-title":"J. Immunol. Baltim. Md. 1950"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114048_bb0910","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0165-4608(95)00169-7","article-title":"Cytogenetic findings in mouse multiple myeloma and Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"86","author":"van den Akker","year":"1996","journal-title":"Cancer Genet. Cytogenet."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114048_bb0915","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/bjc.1987.241","article-title":"The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow","volume":"56","author":"Croese","year":"1987","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0920","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/bjc.1992.415","article-title":"A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL\/KaLwRij mouse","volume":"66","author":"Manning","year":"1992","journal-title":"Br. J. Cancer"},{"issue":"28","key":"10.1016\/j.jconrel.2025.114048_bb0925","doi-asserted-by":"crossref","first-page":"20119","DOI":"10.18632\/oncotarget.24614","article-title":"Mouse models of multiple myeloma: technologic platforms and perspectives","volume":"9","author":"Rossi","year":"2018","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.jconrel.2025.114048_bb0930","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood.V116.21.4077.4077","article-title":"A novel murine model of human disseminated multiple myeloma with a subcutaneous human bone chip from an adult donor confers proliferative advantage and is suitable for the in vivo evaluation of novel drugs","volume":"116","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jconrel.2025.114048_bb0935","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1208\/s12249-014-0177-9","article-title":"Nanomedicine scale-up technologies: feasibilities and challenges","volume":"15","author":"Paliwal","year":"2014","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"10.1016\/j.jconrel.2025.114048_bb0940","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3390\/biom13101497","article-title":"Enabling mRNA therapeutics: current landscape and challenges in manufacturing","volume":"13","author":"Youssef","year":"2023","journal-title":"Biomolecules"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925006698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925006698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:17:50Z","timestamp":1778944670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925006698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":188,"alternative-id":["S0168365925006698"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114048","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in RNA therapeutics and its delivery strategies against Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114048"}}